{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:09:19Z","timestamp":1789038559994,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04561-9","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:20:00Z","timestamp":1789035600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline fdg pet\/ct-derived tumor burden and host metabolic activity predict complete metabolic response to neoadjuvant chemotherapy in \u0131nvasive ductal breast cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2987","authenticated-orcid":false,"given":"Alev","family":"Cinar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra Demirtas","family":"Senlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayberk","family":"Inanir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Tatc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-1626","authenticated-orcid":false,"given":"Ozlem","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"4561_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4561_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"4561_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindie E, Delord M, Giacchetti S, Hamy AS, de Roquancourt A, et al. Prognostic impact of 18F-FDG PET\/CT findings in clinical stage II and III breast cancer. J Natl Cancer Inst. 2012;104:1879\u201387.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"4561_CR4","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, Alberini JL, Hindi\u00e9 E, Mankoff D. 18F-FDG PET\/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):17S-26S.","journal-title":"J Nucl Med"},{"key":"4561_CR5","first-page":"1458","volume":"23","author":"AM Garcia Vicente","year":"2021","unstructured":"Garcia Vicente AM, Soriano Castrej\u00f3n A, Le\u00f3n Mart\u00edn A, Chac\u00f3n L-M. Baseline metabolic tumor burden and response prediction in breast cancer. Clin Transl Oncol. 2021;23:1458\u201366.","journal-title":"Clin Transl Oncol"},{"key":"4561_CR6","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1245\/s10434-019-07325-8","volume":"26","author":"T Higuchi","year":"2019","unstructured":"Higuchi T, Nishimukai A, Ozawa H, Bun A, Fukui R, Miyagawa Y, et al. Significance of metabolic tumor volume at baseline and reduction of metabolic tumor volume after neoadjuvant chemotherapy in breast cancer patients. Ann Surg Oncol. 2019;26:3363\u201373.","journal-title":"Ann Surg Oncol"},{"key":"4561_CR7","first-page":"1255","volume":"21","author":"SH Hyun","year":"2014","unstructured":"Hyun SH, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, et al. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with pathological complete response in breast cancer. Ann Surg Oncol. 2014;21:1255\u201363.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"4561_CR8","doi-asserted-by":"publisher","first-page":"55S","DOI":"10.2967\/jnumed.108.057240","volume":"50","author":"N Avril","year":"2009","unstructured":"Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med. 2009;50(Suppl 1):55S-63S.","journal-title":"J Nucl Med"},{"key":"4561_CR9","first-page":"939","volume":"71","author":"K Kitajima","year":"2016","unstructured":"Kitajima K, Fukushima K, Miyoshi Y, Katsuura T, Igarashi Y, Kawanaka Y,  et al. Diagnostic and prognostic value of FDG PET\/CT in breast cancer. Clin Radiol. 2016;71:939\u201349.","journal-title":"Clin Radiol"},{"key":"4561_CR10","first-page":"1529","volume":"42","author":"O Humbert","year":"2015","unstructured":"Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B\u00a0et al. HER2-positive breast cancer: FDG PET for early prediction of response to neoadjuvant therapy. Eur J Nucl Med Mol Imaging. 2015;42:1529\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4561_CR11","first-page":"500","volume":"43","author":"DA Mankoff","year":"2002","unstructured":"David A. Mankoff, Lisa K. Dunnwald, Julie R. Gralow, Georgiana K. Ellis, Aaron Charlop, Thomas J. Lawton,\u00a0et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500\u20139.","journal-title":"J Nucl Med"},{"key":"4561_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001227","volume":"148","author":"A Toriihara","year":"2022","unstructured":"Pak K, Seok JW, Kim HY, Nguyen TL, Kim K, Kim SJ\u00a0et al.\u00a0Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis. Nucl Med Commun. 2020 Aug;41(8):824-829. https:\/\/doi.org\/10.1097\/MNM.0000000000001227. PMID: 32516244.","journal-title":"Eur J Radiol"},{"key":"4561_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225959","volume":"14","author":"W Wen","year":"2019","unstructured":"Wen W, Xuan D, Hu Y, Li X, Liu L, Xu D. Prognostic value of maximum standardized uptake value, metabolic tumor volume and total lesion glycolysis in breast cancer: a systematic review and meta-analysis. PLoS ONE. 2019;14:e0225959.","journal-title":"PLoS ONE"},{"key":"4561_CR14","volume":"15","author":"JW Lee","year":"2020","unstructured":"Jeong Won Lee, Ik Dong Yoo, Sun-pyo Hong, Beodeul Kang, Jung Sun Kim, Yung Kil Kimet al. Prognostic significance of bone marrow FDG uptake in breast cancer. PLoS ONE. 2020;15:e0234345.","journal-title":"PLoS ONE"},{"key":"4561_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208861","volume":"13","author":"JI Bang","year":"2018","unstructured":"Bang JI, Yoon HJ, Kim BS. Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET\/CT for prediction of tumor recurrence in breast cancer. PLoS One. 2018 Dec 7;13(12):e0208861. https:\/\/doi.org\/10.1371\/journal.pone.0208861. PMID: 30532215; PMCID: PMC6286142.","journal-title":"PLoS ONE"},{"key":"4561_CR16","first-page":"6120","volume":"31","author":"SJ Lee","year":"2021","unstructured":"Inoue, Kentaro Goto, Ryoi Okada, Ken Kinomura, Shigeo Fukuda, Hiroshi. (2009). A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Annals of Nuclear Medicine. 23. 643-649. 10.1007\/s12149-009-0286-9. . Bone marrow-to-liver uptake ratio as an imaging biomarker of systemic inflammation. Eur Radiol. 2021;31:6120\u20138.","journal-title":"Eur Radiol"},{"key":"4561_CR17","doi-asserted-by":"crossref","unstructured":"Dowling GP, Daly GR, Hegarty A, Hembrecht S, Bracken A, Toomey S, et al. Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis. BJS. 2024;111(5):znae132.","DOI":"10.1093\/bjs\/znae132"},{"key":"4561_CR18","unstructured":"Humbert O, Leli\u00e8vre B, Dietemann S, Dubreuil J, Tissot C, Riedinger JM, et al. 18F-FDG PET\/CT in the early prediction of pathological response to neoadjuvant therapy in breast cancer: review and recommendations. Eur J Nucl Med Mol Imaging. 2023."},{"key":"4561_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219898504","author":"S Arici","year":"2020","unstructured":"Arici S, Karyagar SS, Karyagar S, Geredeli C, Cekin R, Secmeler S, et al. The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer. J Oncol Pharm Pract. 2020. https:\/\/doi.org\/10.1177\/1078155219898504.","journal-title":"J Oncol Pharm Pract"},{"key":"4561_CR20","doi-asserted-by":"crossref","unstructured":"Vaz SC, Pilkington Woll JP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM\u2013SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024.","DOI":"10.1007\/s00259-024-06696-9"},{"key":"4561_CR21","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CMM Prado","year":"2009","unstructured":"Prado CMM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920\u20136.","journal-title":"Clin Cancer Res"},{"key":"4561_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58\u201367.","journal-title":"Eur J Cancer"},{"key":"4561_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00520-017-3902-6","volume":"26","author":"E Deluche","year":"2018","unstructured":"Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N. Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer. 2018;26:861\u20138.","journal-title":"Support Care Cancer"},{"key":"4561_CR24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jcsm.12579","volume":"11","author":"GFP Aleixo","year":"2020","unstructured":"Aleixo GFP, Williams GR, Nyrop KA, Muss HB, Shachar SS. Muscle composition and outcomes in patients with breast cancer: a systematic review. J Cachexia Sarcopenia Muscle. 2020;11:1177\u201392.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"Suppl 1","key":"4561_CR25","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R. Standards for PET image acquisition and quantitative analyses. J Nucl Med. 2009;50(Suppl 1):11S-20S.","journal-title":"J Nucl Med"},{"key":"4561_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04561-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:20:06Z","timestamp":1789035606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04561-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":26,"alternative-id":["4561"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04561-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest related to this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the Ethics Committee of University of Health Sciences, Ankara Etlik City Hospital (Approval No: 2024-643).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We received written consent from all patients for this study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}